A Phase 2 interventional study of PF-03084014 and Gemcitabine in Metastatic Cancer Pancreas, sponsored by Pfizer. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-10.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Pancreatic Neoplasms by Pfizer — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatic Neoplasms · Pfizer.
Among the 25 studies in Pancreatic Neoplasms by Pfizer, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 2, and was the 13th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.
Browse Pancreatic Neoplasms studies →3 of the 25 studies in Pancreatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Pfizer · Sites in United States, Canada, China and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 11 · Phase 3 2 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 79 across the 24 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Pancreatic Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-03084014 in combination with gemcitabine and nab-paclitaxel
Drug: PF-03084014 · Drug: Gemcitabine · Drug: Nab-paclitaxel
PF-03084014 in combination with gemcitabine and nab-paclitaxel
Drug: PF-03084014 · Drug: Gemcitabine · Drug: Nab-paclitaxel
Gemcitabine plus nab-Paclitaxel
Drug: Gemcitabine · Drug: Nab-paclitaxel
Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Also known as: Abraxane
Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Also known as: Abraxane
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
Also known as: Abraxane
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1
DLT was defined as any of the following events occurring during the first cycle of treatment and considered at least possibly-related to study medication: any Grade 3 or 4 clinically-relevant non-hematologic and/or hematologic toxicity, delay of more than 2 weeks in receiving the next scheduled cycle due to persisting treatment-related toxicities.
Time frame: Cycle 1 (28 days)
Overall Survival (OS) in Phase 2
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)
Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.
Time frame: Baseline up to 28-35 days post last administration of study drug
Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 2
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.
Time frame: Baseline up to 28-35 days post last administration of study drug
Number of Participants With Laboratory Abnormalities in Phase 1
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).
Time frame: Screening; Cycle 1 Days 1, 8, 15, 22; up to 28-35 days post last administration of study drug
Number of Participants With Laboratory Abnormalities in Phase 2
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).
Time frame: Screening; Days 1, 8, 15 of each cycle; up to 28-35 days post last administration of study drug
Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Phases 1 and 2
Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate, weight and body surface area.
Time frame: Baseline up to 28-35 days after treatment discontinuation
Number of Participants With Worsening QTc Results in Phase 1
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.
Time frame: Screening, Cycle 1 Days 3 and 22, Cycles 2 and 3 Day 1, end of treatment
Number of Participants With Worsening QTc Results in Phase 2
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.
Time frame: Screening, Cycle 1 Days 1 and 22, Cycles 2 and 3 Day 1, end of treatment
Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1
AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau, tau=12 hours), and AUC from time 0 to last measured concentration (AUClast).
Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 2
AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau), and AUC from time 0 to last measured concentration (AUClast).
Time frame: Cycle 1 Day 1 till end of last cycle
Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1
Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 2
Time frame: Cycle 1 Day 1 till end of last cycle
Systemic Clearance (CL) of Nab-paclitaxel in Phase 1
Time frame: Cycle 1 Days 1-3, and 15-17
Systemic Clearance (CL) of Gemcitabine in Phase 1
Time frame: Cycle 1 Days 1 and 15
Systemic Clearance (CL) of PF-03084014, Nab-P and GEM in Phase 2
Time frame: Cycle 1 Day 1 till end of last cycle
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 1
Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 2
Time frame: Cycle 1 Day 1 till end of last cycle
Volume of Distribution at Steady State (Vss) for Nab-P and GEM in Phase 1
Time frame: Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)
Volume of Distribution at Steady State (Vss) for PF-03084014, Nab-P and GEM in Phase 2
Time frame: Cycle 1 Day 1 till end of last cycle
Plasma Decay Half-life (t1/2) for Nab-P and GEM in Phase 1
Time frame: Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)
Plasma Decay Half-life (t1/2) for PF-03084014, Nab-P and GEM in Phase 2
Time frame: Cycle 1 Day 1 till end of last cycle
Number of Participants With Objective Response (OR) in Phase 1
Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Screening till 28-35 days post last administration of study drug
Number of Participants With Objective Response (OR) in Phase 2
Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Screening till 28-35 days post last administration of study drug
Duration of Response (DR) for Phases 1 and 2
Duration of response (DR) defined as the difference in days between the first date criteria for progression occurred or the participant died due to any cause and the first date that criteria for a PR or CR were met. DR calculated as (months) = (progression/death date - first date of OR + 1) divided by 30.4. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity (up to 5 years)
1-year and 2-year OS in Phase 2
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)
Progression-free Survival (PFS) in Phase 2
PFS was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression or death on study due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - date of randomization +1) divided by 30.4.
Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)
Brief Pain Inventory-Short Form (BPI-sf) Score - Phase 2
BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
Time frame: Day 1 of Cycle 1 and subsequent cycles; end of treatment
Change From Baseline in European Quality of Life Questionnaire (EQ-5D) - Phase 2
EQ-5D: 6-item participant rated questionnaire to assess health-related quality of life in terms of a single utility score. There were 2 components: a Health State Profile and a Visual Analog Scale. Published weights are available that allow for the creation of a single summary score. Overall scores range from 0-1, with low scores representing a higher level of dysfunction.
Time frame: Baseline till end of treatment
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC QLQ-C30) - Phase 2
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline till end of treatment
The study planned to include 2 phases: Phase 1 (dose-finding phase) followed by Phase 2 (randomized phase). Due to early termination of the study, only 3 participants were enrolled in Phase 1 and Phase 2 was not conducted.
| Milestone | PF-03084014+Nab-Paclitaxel+Gemcitabine |
|---|---|
| Started | 3 |
| Completed | 0 |
| Not completed | 3 |
| Withdrew: Symptomatic deterioration | 2 |
| Withdrew: Adverse event | 1 |
DLT was defined as any of the following events occurring during the first cycle of treatment and considered at least possibly-related to study medication: any Grade 3 or 4 clinically-relevant non-hematologic and/or hematologic toxicity, delay of more than 2 weeks in receiving the next scheduled cycle due to persisting treatment-related toxicities.
| participants | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | 2 |
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
No measurements were reported for this outcome.
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.
| participants | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| All-causality TEAEs | 3 |
| Treatment-related TEAEs | 3 |
| Grade 3 or 4 TEAEs | 3 |
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.
No measurements were reported for this outcome.
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).
| participants | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Number of Participants With Laboratory Abnormalities in Phase 1 | 3 |
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).
No measurements were reported for this outcome.
Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate, weight and body surface area.
No measurements were reported for this outcome.
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.
| participants | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Number of Participants With Worsening QTc Results in Phase 1 | NA |
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.
No measurements were reported for this outcome.
AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau, tau=12 hours), and AUC from time 0 to last measured concentration (AUClast).
| nanogram*hour/milliliter (ng*hr/mL) | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| AUClast for PF-03084014 on Day 3 (n=3) | 1122 ± 913 |
| AUClast for PF-03084014 on Day 15 (n=1) | 1770 ± NA |
| AUCinf for nab-paclitaxel on Day 1 (n=3) | 5774 ± 11 |
| AUClast for nab-paclitaxel on Day 1 (n=3) | 5185 ± 9 |
| AUCinf for nab-paclitaxel on Day 15 (n=1) | 5050 ± NA |
| AUClast for nab-paclitaxel on Day 15 (n=1) | 4600 ± NA |
| AUCinf for gemcitabine on Day 1 (n=3) | 5316 ± 172 |
| AUClast for gemcitabine on Day 1 (n=3) | 5262 ± 176 |
| AUCinf for gemcitabine on Day 15 (n=1) | 2510 ± NA |
| AUClast for gemcitabine on Day 15 (n=1) | 2500 ± NA |
AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau), and AUC from time 0 to last measured concentration (AUClast).
No measurements were reported for this outcome.
| nanogram/milliliter (ng/mL) | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Cmax for PF-03084014 on Day 3 (n=3) | 527.3 ± 710 |
| Cmax for PF-03084014 on Day 15 (n=1) | 943.0 ± NA |
| Cmax for nab-paclitaxel on Day 1 (n=3) | 6023 ± 6 |
| Cmax for nab-paclitaxel on Day 15 (n=1) | 5140 ± NA |
| Cmax for gemcitabine on Day 1 (n=3) | 10760 ± 212 |
| Cmax for gemcitabine on Day 15 (n=1) | 3620 ± NA |
No measurements were reported for this outcome.
| liter (L)/hour (hr) | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Day 1 (n=3) | 37.88 ± 25 |
| Day 15 (n=1) | 38.60 ± NA |
| liter (L)/minute (min) | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Day 1 (n=3) | 5.434 ± 165 |
| Day 15 (n=1) | 8.160 ± NA |
No measurements were reported for this outcome.
| hours | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Tmax of PF-03084014 on Day 3 (n=3) | 1.23 (0.517 to 4.13) |
| Tmax of PF-03084014 on Day 15 (n=1) | 0.900 (NA to NA) |
| Tmax of nab-paclitaxel on Day 1 (n=3) | 0.550 (0.517 to 0.583) |
| Tmax of nab-paclitaxel on Day 15 (n=1) | 0.217 (NA to NA) |
| Tmax of gemcitabine on Day 1 (n=3) | 0.517 (0.250 to 0.533) |
| Tmax of gemcitabine on Day 15 (n=1) | 0.350 (NA to NA) |
No measurements were reported for this outcome.
| liters | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Vss of nab-paclitaxel on Day 1 (n=3) | 64.46 ± 6 |
| Vss of nab-paclitaxel on Day 15 (n=1) | 60.80 ± NA |
| Vss of gemcitabine on Day 1 (n=3) | 61.76 ± 186 |
| Vss of gemcitabine on Day 15 (n=1) | 201.0 ± NA |
No measurements were reported for this outcome.
| hours | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| t1/2 of nab-paclitaxel on Day 1 (n=3) | 2.500 ± 0.26851 |
| t1/2 of nab-paclitaxel on Day 15 (n=1) | 2.030 ± NA |
| t1/2 of gemcitabine on Day 1 (n=3) | 0.2813 ± 0.14838 |
| t1/2 of gemcitabine on Day 15 (n=1) | 0.2230 ± NA |
No measurements were reported for this outcome.
Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| participants | PF-03084014 + Nab-Paclitaxel + Gemcitabine |
|---|---|
| Number of Participants With Objective Response (OR) in Phase 1 | 0 |
Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
No measurements were reported for this outcome.
Duration of response (DR) defined as the difference in days between the first date criteria for progression occurred or the participant died due to any cause and the first date that criteria for a PR or CR were met. DR calculated as (months) = (progression/death date - first date of OR + 1) divided by 30.4. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
No measurements were reported for this outcome.
Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
No measurements were reported for this outcome.
PFS was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression or death on study due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - date of randomization +1) divided by 30.4.
No measurements were reported for this outcome.
BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
No measurements were reported for this outcome.
EQ-5D: 6-item participant rated questionnaire to assess health-related quality of life in terms of a single utility score. There were 2 components: a Health State Profile and a Visual Analog Scale. Published weights are available that allow for the creation of a single summary score. Overall scores range from 0-1, with low scores representing a higher level of dysfunction.
No measurements were reported for this outcome.
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
No measurements were reported for this outcome.
Collected over Baseline through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-03084014+Nab-Paclitaxel+Gemcitabine | — | 2/3 (66.7%) | 3/3 (100%) |
| Event | PF-03084014+Nab-Paclitaxel+Gemcitabine |
|---|---|
| VomitingGastrointestinal disorders | 1/3 |
| Alanine aminotransferase increasedInvestigations | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 1/3 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/3 |
| Event | PF-03084014+Nab-Paclitaxel+Gemcitabine |
|---|---|
| FatigueGeneral disorders | 3/3 |
| NauseaGastrointestinal disorders | 2/3 |
| VomitingGastrointestinal disorders | 2/3 |
| Alanine aminotransferase increasedInvestigations | 2/3 |
| Aspartate aminotransferase increasedInvestigations | 2/3 |
| AscitesGastrointestinal disorders | 1/3 |
| ChillsGeneral disorders | 1/3 |
| Mucosal inflammationGeneral disorders | 1/3 |
| Candida infectionInfections and infestations | 1/3 |
| FallInjury, poisoning and procedural complications | 1/3 |
| Age, Continuous(years) | PF-03084014+Nab-Paclitaxel+Gemcitabine |
|---|---|
| Mean | 64.3 ± 4.7 |
| Sex: Female, Male(Participants) | PF-03084014+Nab-Paclitaxel+Gemcitabine |
|---|---|
| Female | 2 |
| Male | 1 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2014 to primary completion in Nov 2014, 2 months.
Results were first posted in Jun 2017, 2 years 7 months after primary completion. A results delay was requested in Dec 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirogacestat